2023
881. Saliva-Based, Extraction-Free PCR Testing For The Detection Of Key Respiratory Pathogens
Allicock O, Lin T, Fajardo K, Yolda-Carr D, Hislop M, Wang J, Zuniga D, Platt W, Tuohy B, Peno C, Wyllie A. 881. Saliva-Based, Extraction-Free PCR Testing For The Detection Of Key Respiratory Pathogens. Open Forum Infectious Diseases 2023, 10: ofad500.926. PMCID: PMC10677551, DOI: 10.1093/ofid/ofad500.926.Peer-Reviewed Original ResearchSARS-CoV-2Saliva samplesRespiratory virusesRespiratory pathogensSARS-CoV-2 PCR testInfluenza A/BSARS-CoV-2 testingUpper respiratory tract pathogensAdditional respiratory virusesDetection of hMPVMass testing strategyPCR testCommon respiratory virusesCommon respiratory pathogensRespiratory tract pathogensKey respiratory pathogensYears of ageSARS-CoV-2 detectionGrant/research supportTransmissible infectious diseasesUse of salivaYale HealthRespiratory symptomsInfluenza B.Nasopharyngeal swabsThe potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity
Laxton C, Peno C, Hahn A, Allicock O, Perniciaro S, Wyllie A. The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity. The Lancet Microbe 2023, 4: e837-e850. PMID: 37516121, DOI: 10.1016/s2666-5247(23)00135-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSARS-CoV-2Respiratory pathogensPotential of salivaUsefulness of salivaUse of salivaRespiratory specimenRespiratory secretionsDisease burdenImmunological componentsImmunity surveillanceClinical utilityHost immunityClinical useDiagnostic testsNon-invasive natureSalivaCOVID-19 pandemicSample typesMethodological factorsPathogensImmunitySecretion
2022
Association of Upper Respiratory Streptococcus pneumoniae Colonization With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Adults
Parker A, Jackson N, Awasthi S, Kim H, Alwan T, Wyllie A, Baldwin A, Brennick N, Moehle E, Giannikopoulos P, Kogut K, Holland N, Mora-Wyrobek A, Eskenazi B, Riley L, Lewnard J. Association of Upper Respiratory Streptococcus pneumoniae Colonization With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Adults. Clinical Infectious Diseases 2022, 76: 1209-1217. PMID: 36401872, DOI: 10.1093/cid/ciac907.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSARS-CoV-2Upper airwayAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere acute respiratory syndrome coronavirus 2Syndrome coronavirus 2 infectionAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2SARS-CoV-2 molecular testingCoronavirus 2 infectionStreptococcus pneumoniae colonizationViral respiratory pathogensSyndrome coronavirus 2Conditional logistic regressionWorking-age adultsQuantitative polymerase chain reactionPneumococcal carriersPneumococcal carriagePneumoniae colonizationOutpatient clinicCoronavirus 2Polymerase chain reactionRespiratory pathogensSaliva specimens
2020
Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19
Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, Dela Cruz C, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Barakat LA. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurology 2020, 20: 248. PMID: 32552792, PMCID: PMC7301053, DOI: 10.1186/s12883-020-01812-2.Peer-Reviewed Original ResearchConceptsInitial presentationCentral nervous system inflammationSARS-CoV-2 infectionCSF inflammatory markersNervous system inflammationCerebrospinal fluid (CSF) cytokinesSeizure-like activityCOVID-19 infectionVirus SARS-CoV-2COVID-19SARS-CoV-2BackgroundCOVID-19Inflammatory markersNeurologic complicationsSystem inflammationImmunocompromised womanNeurologic manifestationsNeurologic symptomsViral neuroinvasionCase presentationWeInfected patientsMental statusRespiratory pathogensConclusionOur findingsInflammation
2016
Development of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis
Prevaes SM, de Winter-de Groot KM, Janssens HM, de Steenhuijsen Piters WA, Tramper-Stranders GA, Wyllie AL, Hasrat R, Tiddens HA, van Westreenen M, van der Ent CK, Sanders EA, Bogaert D. Development of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2016, 193: 504-515. PMID: 26492486, DOI: 10.1164/rccm.201509-1759oc.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsBurkholderiaBurkholderia InfectionsCarrier StateCase-Control StudiesCohort StudiesCorynebacteriumCorynebacterium InfectionsCystic FibrosisDNA, BacterialEnterobacteriaceaeEnterobacteriaceae InfectionsFemaleHaemophilus InfectionsHaemophilus influenzaeHumansInfantInfant, NewbornMaleMicrobiotaMoraxellaMoraxellaceae InfectionsNasopharynxProspective StudiesReal-Time Polymerase Chain ReactionRNA, Ribosomal, 16SStaphylococcal InfectionsStaphylococcus aureusStreptococcal InfectionsStreptococcus mitisConceptsHealthy control subjectsControl subjectsMonths of lifeMonths of ageCystic fibrosisAntibiotic useMicrobiota profilesAge-matched healthy control subjectsEarly structural lung diseaseNasopharyngeal microbiota profilesNasopharynx of infantsProspective cohort studyStructural lung diseaseTime of diagnosisMoraxella sppPotential respiratory pathogensRespiratory symptomsAntibiotic therapyCohort studyPulmonary infectionLung diseaseNasopharyngeal microbiotaRespiratory pathogensHaemophilus influenzaeNasopharynx samples